Dr Reddys Laboratories' Q4 FY 2025-26 Quarterly Results

Result Summary

• Dr Reddys Laboratories Ltd reported a 11.1% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 11.4%.
• Its expenses for the quarter were up by 1.2% QoQ and 8.5% YoY.
• The net profit decreased 81.4% QoQ and decreased 86.1% YoY.
• The earnings per share (EPS) of Dr Reddys Laboratories Ltd stood at 2.65 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Dr. Reddy's Laboratories Ltd is a prominent multinational pharmaceutical company based in India. The company is primarily engaged in the manufacturing and marketing of a wide range of pharmaceutical products. These include generic medications, active pharmaceutical ingredients (APIs), and branded formulations. Dr. Reddy's operates globally, with a significant presence in markets like the United States, Europe, India, and Russia. The company is renowned for its focus on research and development, aiming to innovate cost-effective and high-quality medications to meet diverse healthcare needs. As of the latest available data, Dr. Reddy's continues to expand its portfolio through strategic acquisitions and partnerships, enhancing its capability to address complex diseases and expand its global footprint.

Revenue

In the fourth quarter of the fiscal year 2026, Dr. Reddy's Laboratories reported a total income of ₹8021.80 crores. This reflected a decrease compared to the previous quarter (Q3FY26), which recorded a total income of ₹9022.20 crores, marking an 11.1% quarter-over-quarter (QoQ) decline. Additionally, there was a decrease when compared to the same quarter in the previous year (Q4FY25), which had a total income of ₹9050.50 crores, resulting in an 11.4% year-over-year (YoY) decline. Such fluctuations in revenue are common in the pharmaceutical industry due to various factors, including changes in product demand, market dynamics, and regulatory developments.

Profitability

During Q4FY26, Dr. Reddy's Laboratories' profitability metrics showed significant changes. The company recorded a profit before tax (PBT) of ₹195.10 crores, a substantial decline of 87.3% from the previous quarter's PBT of ₹1540.90 crores. This also marked a 90.2% decrease from the PBT of ₹1999.70 crores in Q4FY25. The tax expense for Q4FY26 was negative at ₹-21.60 crores, compared to ₹353.60 crores in Q3FY26 and ₹418.50 crores in Q4FY25. Consequently, the profit after tax (PAT) for Q4FY26 was ₹221.30 crores, which was an 81.4% decline from Q3FY26's PAT of ₹1189.60 crores and an 86.1% decrease from the ₹1586.70 crores reported in Q4FY25. Earnings per share (EPS) for Q4FY26 stood at ₹2.65, down from ₹14.52 in the previous quarter and ₹19.10 in the same quarter last year.

Operating Metrics

The total expenses for Dr. Reddy's Laboratories in Q4FY26 were reported at ₹7569.20 crores. This represented a slight increase of 1.2% from the previous quarter's expenses of ₹7481.30 crores and an 8.5% increase compared to the expenses of ₹6974.00 crores in Q4FY25. The analysis of operating metrics, including expenses, is crucial for understanding the cost management and efficiency of the company. Although revenue has declined, the increase in expenses may be attributed to various operational factors, including production costs, research and development, and marketing expenses. These metrics are essential for assessing the company's operational performance and strategic focus in managing its resources effectively.